Date of first round report: 1 September 2016 Date of second round report: 30 January 2017



Download 8.29 Mb.
Page25/53
Date conversion16.05.2018
Size8.29 Mb.
1   ...   21   22   23   24   25   26   27   28   ...   53

Results for other efficacy outcomes


In the updates with 23 October 2015 and 16 March 2015 cut-off dates, results were also presented for OR, ‘CBR’, DoR; with 112 (57% of the required 198 OS events) deaths at the most recent cut-off (23 October 2015), the OS data are too immature for analysis.
Objective response

In the ITT population OR (CR/PR) rates were higher in the treatment than the control arm, but in the analysis from the data cutoff date of 23 October 2015:

  • the ITT investigator-assessed OR rate was 21.0% (95% CI: 16.9-25.7) in the palbociclib plus fulvestrant arm and 8.6% (95% CI: 4.9-13.8) in the placebo plus fulvestrant arm;

  • the odds ratio was 2.78 (95% CI: 1.56-5.60) in favour of palbociclib plus fulvestrant treatment, with a stratified 1-sided p-value of 0.0001.

The sponsor provided additional analyses for endpoints that were not listed in the study design with this latest data cut-off, including the OR for patients with measurable disease.

Table 16: Study A5481023 Summary of objective response, clinical benefit response and duration of objective response – Investigator assessed as of 23 October 2015, ITT population



In the ITT population, 4 patients (2.9%) achieved a CR in the control arm compared with none (0%) in the treatment arm, while 21% in the treatment arm achieved a PR compared with 6.3% in the control arm. SD was reported in 52.5% (42.5%>24 weeks) of the palbociclib and fulvestrant arm compared with 41.3% (31%>24 weeks).

The objective progression rate (progression without any response) was 17% in the palbociclib and fulvestrant arm compared with 33% in the comparator arm.

Comment: For the first time, the OR is now statistically significantly improved in the palbociclib and fulvestrant arm. However, the OR for those with measurable disease was not a secondary endpoint and involves a subgroup analysis that was not prespecified and therefore should not be included in PI and the sponsor is requested to remove this in providing an updated PI.

1   ...   21   22   23   24   25   26   27   28   ...   53


The database is protected by copyright ©dentisty.org 2016
send message

    Main page